People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35222
- Alabama (Site ID: 31788)
-
Contact:
- Heather Logan
- Phone Number: 205-934-6774
- Email: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, United States, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Contact:
- Aleen Khodabakhshian
- Phone Number: 310-557-3798
- Email: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, United States, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Contact:
- Dawn Rosenblum
- Phone Number: 619-543-8080
- Email: drosenblum@health.ucsd.edu
-
San Francisco, California, United States, 94110
- University of California, San Francisco (Site ID: 801)
-
Contact:
- Jay Dwyer
- Phone Number: 415-502-5748
- Email: jay.dwyer@ucsf.edu
-
Torrance, California, United States, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Contact:
- Mario Guerrero
- Phone Number: 323-457-1459
- Email: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Contact:
- Nicola Haakonsen
- Phone Number: 303-724-5931
- Email: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Contact:
- Avery Wimpelberg
- Phone Number: 202-797-3589
- Email: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University (Site ID: 2701)
-
Contact:
- Sherryl L Wolfe
- Phone Number: 312-695-4997
- Email: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University (Site ID: 201)
-
Contact:
- Rebecca L Becker
- Phone Number: 410-614-4036
- Email: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Contact:
- Amy Sbrolla
- Phone Number: 617-726-5598
- Email: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Contact:
- Hannah Jordan
- Phone Number: 617-732-4785
- Email: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Contact:
- Christie Lyn Costanza
- Phone Number: 972-972-9069
- Email: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, United States, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Contact:
- Mauricio Vergara
- Phone Number: 212-746-7204
- Email: mav9177@med.cornell.edu
-
New York, New York, United States, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Contact:
- Keisha Ballentine-Cargill
- Phone Number: 212-746-7804
- Email: keb4006@med.cornell.edu
-
New York, New York, United States, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Contact:
- Brett T Gray
- Phone Number: 212-305-1570
- Email: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Contact:
- Erin Elizabeth Hoffman
- Phone Number: 919-843-0720
- Email: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, United States, 27401-1020
- Greensboro (Site ID: 3203)
-
Contact:
- Kelly Phillips
- Phone Number: 336-832-7297
- Email: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Contact:
- Michelle Saemann
- Phone Number: 513-584-2245
- Email: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, United States, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Contact:
- Julie Pasternak
- Phone Number: 216-844-2738
- Email: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, United States, 43210
- Ohio State University (Site ID: 2301)
-
Contact:
- Lindsay Summers
- Phone Number: 614-293-8529
- Email: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh (Site ID: 1001)
-
Contact:
- Stacey Edick
- Phone Number: 412-383-1748
- Email: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, United States, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Contact:
- Beverly Woodward
- Phone Number: 615-936-8516
- Email: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Contact:
- Maria Laura Martinez
- Phone Number: 713-500-6718
- Email: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Contact:
- Allysson Angeldekao
- Phone Number: 503-715-7324
- Email: allysson@uw.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 48
|
Baseline through Week 48
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Time Frame: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Time Frame: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Time Frame: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Time Frame: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Time Frame: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Time Frame: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Time Frame: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Time Frame: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Time Frame: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Time Frame: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Time Frame: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Time Frame: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Time Frame: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Time Frame: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Time Frame: Week 48
|
Week 48
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A5431
- 39159 (Other Identifier: DAIDS-ES ID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data that underlie results in the publication after deidentification
IPD Sharing Time Frame
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD Sharing Access Criteria
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.